HIV treatment resistance is permanent and irreversible, which can jeopardize future treatment options for PWH. Food and Drug Administration (FDA) approved a new, expanded indication for Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. Biktarvy Is a Long-Term Treatment Option with a High Barrier to Resistance for a Broad Range of Individuals -įOSTER CITY, Calif., February 26, 2024-( BUSINESS WIRE)-Gilead Sciences, Inc. M184V/I One of the Most Common Forms of Resistance Among People with HIV. For replacement cards and support for pharmacists, please visit .- Biktarvy Now First and Only INSTI-Based Single-Tablet Regimen That is FDA Approved and DHHS Guideline Recommended for People Who are Virologically Suppressed with M184V/I Resistance. Patients seeking co-pay assistance for specific drugs should visit the manufacturer’s website. With each claim, the provider receives an EOB that clearly communicates the patient’s program status and remaining benefits.Īre you a patient looking for co-pay assistance?.The medical co-pay program provides prompt payment to the provider by check or direct deposit.(This step ensures only eligible providers and patients receive reimbursement for covered products.) Each claim gets reviewed for compliance with the program rules.The provider faxes a claim form, along with the patient’s commercial insurance evidence of benefits (EOB), to bill the program.Our medical co-pay program is a simple process that follows these steps: We also provide ongoing adherence coaching for patients to help them overcome barriers, set expectations and deter drop off. We engage and educate provider staff in the processes of enrollment, claims submission and payment. Our team of experts will work to understand your financial support needs, building an integrated co-pay solution to help you serve patients and promote loyalty. Depending on a patient’s product portfolio and provider coverage, brands may offer medical or pharmacy benefit support-or both.

Specialty brands often require medical benefit co-pay programs, particularly for infused and in-office administered products. Operational integration to hub services for applicable brandsĬustomized medical benefit co-pay assistance programs.Print, including program materials, direct mail, and ongoing fulfillment.Interactive Voice Response (IVR) and live support.Digital support, including web and mobile.Phone-based adherence coaching through trained adherence-support representatives.It also offers multi-channel support, sending patients relevant messages based on actions or inactivity including: LoyaltyScript helps tens of thousands of patients save money on their medications every day. Help patients overcome financial barriers to adherence with our trusted pharmacy co-pay support solution, LoyaltyScript®. LoyaltyScript, McKesson's market-leading pharmacy co-pay solution We offer programs for pharmacy co-pay and medical benefit co-pay, and we work with you to determine how they can best support your business. McKesson can help you ensure patients can overcome the barriers to medication adherence. The more you can do to support a patient’s ability to adhere to their medication, the better their outcome and the more your business can grow to serve your customers.

Learn more about McKesson solutions for biopharma and life sciences companies.Īs a pharmaceutical manufacturer, your business depends on patients having access to the medications they need.

Gilead biktarvy copay card